Table 2.

Response rates of unirradiated tumors by treatment, target, or treatment sequence

irRC response category, n (%)
CRPRSDPDPa
All patients2 (2)7 (7)16 (17)70 (74)
By treatment group
 Liver 50/4 concurrent01 (5)018 (95)
 Liver 50/4 sequential01 (6)4 (24)12 (70)
 Lung 50/4 concurrent1 (5)2 (9)4 (19)14 (67)
 Lung 50/4 sequential1 (5)1 (5)6 (32)11 (58)
 Liver or lung 60/10 sequential02 (11)2 (11)15 (78)
By stereotactic target0.061
 Liver03 (6)4 (11)36 (83)
 Lung2 (5)4 (7)12 (25)34 (63)
By treatment sequence0.250
 Concurrent1 (2)3 (8)4 (10)32 (80)
 Sequential1 (2)4 (7)12 (22)38 (69)
  • Abbreviations: PD, progressive disease; SCC, squamous cell carcinoma.

  • aReported P value compares clinical benefit (defined as CR, PR, or SD) at 6 months between the concurrent therapy versus sequential therapy groups.